These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38284515)

  • 1. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.
    Qi J; Choi I; Ota S; Ichikawa S; Fujishima N; Iida H; Sugiura I; Sugiura K; Murata Y; Inoue H; Ohwada S; Wang J
    Clin Pharmacol Drug Dev; 2024 May; 13(5):560-571. PubMed ID: 38284515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
    Usuki K; Handa H; Choi I; Yamauchi T; Iida H; Hata T; Ohwada S; Okudaira N; Nakamura K; Sakajiri S
    Int J Hematol; 2019 Dec; 110(6):654-664. PubMed ID: 31359361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
    Altman JK; Foran JM; Pratz KW; Trone D; Cortes JE; Tallman MS
    Am J Hematol; 2018 Feb; 93(2):213-221. PubMed ID: 29139135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
    Takahashi T; Usuki K; Matsue K; Ohno H; Sakura T; Imanaka R; Murakami M; Ohwada S; Takagi T; Sakajiri S
    Int J Hematol; 2019 Dec; 110(6):665-674. PubMed ID: 31473943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in
    Cortes JE; Tallman MS; Schiller GJ; Trone D; Gammon G; Goldberg SL; Perl AE; Marie JP; Martinelli G; Kantarjian HM; Levis MJ
    Blood; 2018 Aug; 132(6):598-607. PubMed ID: 29875101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.
    Kang D; Ludwig E; Jaworowicz D; Huang H; Fiedler-Kelly J; Cortes J; Ganguly S; Khaled S; Krämer A; Levis M; Martinelli G; Perl A; Russell N; Abutarif M; Choi Y; Mendell J; Yin O
    J Clin Pharmacol; 2020 Dec; 60(12):1629-1641. PubMed ID: 32598495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
    Li J; Kankam M; Trone D; Gammon G
    Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics.
    Li J; Trone D; Mendell J; O'Donnell P; Cook N
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):799-807. PubMed ID: 31385001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
    Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
    Martínez-Cuadrón D; Rodríguez-Macías G; Rodríguez-Veiga R; Boluda B; Montesinos P
    Clin Drug Investig; 2020 Mar; 40(3):227-235. PubMed ID: 31912423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quizartinib for the treatment of acute myeloid leukemia.
    Garcia-Horton A; Yee KW
    Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
    Sandmaier BM; Khaled S; Oran B; Gammon G; Trone D; Frankfurt O
    Am J Hematol; 2018 Feb; 93(2):222-231. PubMed ID: 29090473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with
    Bewersdorf JP; Patel KK; Shallis RM; Podoltsev NA; Kewan T; Stempel J; Mendez L; Stahl M; Stein EM; Huntington SF; Goshua G; Zeidan AM
    Leuk Lymphoma; 2024 Aug; 65(8):1136-1144. PubMed ID: 38648559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
    Bhullar J; Natarajan K; Shukla S; Mathias TJ; Sadowska M; Ambudkar SV; Baer MR
    PLoS One; 2013; 8(8):e71266. PubMed ID: 23967177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.